Ardelyx

About Ardelyx

Ardelyx is a pioneering biopharmaceutical company dedicated to transforming the treatment landscape for patients with gastrointestinal and renal diseases. Founded on the principles of innovation and patient-centricity, Ardelyx focuses on developing novel therapies that address unmet medical needs.

The company’s flagship product, Tenapanor, is designed to treat conditions such as irritable bowel syndrome with constipation (IBS-C) and hyperphosphataemia in patients with chronic kidney disease. Ardelyx’s commitment to research and development is evident in its robust pipeline, which includes several promising candidates aimed at improving patient outcomes.

At Ardelyx, we believe in the power of collaboration and actively engage with healthcare professionals, patients, and regulatory bodies to ensure our therapies are safe and effective. Our team comprises experts from diverse backgrounds, united by a common goal: to enhance the quality of life for those suffering from debilitating conditions.

We are headquartered in the UK, where we foster a culture of innovation and excellence. Our state-of-the-art facilities are equipped with cutting-edge technology, enabling us to conduct advanced research and clinical trials.

As we look to the future, Ardelyx remains committed to expanding our portfolio and exploring new therapeutic areas. We aim to be at the forefront of biopharmaceutical advancements, continuously striving to bring hope and healing to patients worldwide.

• Core Values: Innovation, Integrity, Collaboration, Patient-Centricity
• Vision: To be a leader in biopharmaceuticals, delivering transformative therapies to patients in need.